The role of CD4+ T cell responses in antitumor immunity

Current Opinion in Immunology

Volumn 10, Issue 5, 1998, Pages 588-594

  Pardoll, Drew M ^a   Topalian, Suzanne L ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 0031782910     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80228-8     Document Type: Article

References (49)

1. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol. 13:1995;545-586.
2. Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA. 92:1995;2219-2223.
3. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, Ter Schegget J, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 23:1993;2242-2249.
4. Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G, Eisenbach L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Natl Med. 1:1995;1179-1183.
5. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, DeLeo AB. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1:1995;1297-1302.
6. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 60:1990;397-403.
7. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 254:1991;713-716.
8. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky P, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 90:1993;3539-3543.
9. Lin KY, Guarnieri FG, Staveley-O'Carroll K, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21-26.
10. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med. 179:1994;1215-1224.
11. Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol. 6:1994;722-727.
12. +-dependent mechanism. Cancer Res. 53:1993;2112-2117.
13. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol. 149:1992;3627-3635.
14. + T cell-dependent tumor rejection. J Exp Med. 174:1991;1291-1298.
15. Pan ZK, Ikonomidis G, Pardoll D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res. 55:1995;4776-4779.
16. +, 2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med. 161:1985;1122-1134.
17. + cytolytic clones which recognize a tumor-specific cell surface antigen. J Immunol. 135:1985;703-713.
18. Bookman MA, Swerdlow R, Matis LA. Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones. J Immunol. 139:1987;3166-3170.
19. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA. 95:1998;1178-1183.
20. + T cell tolerance to parenchymal self-antigens requires presentation bybone marrow-derived antigen-presenting cells. J Exp Med. 187:1998;1555-1564.
21. + T cell responses to a 'nonproductive' Th2-type differentiation pathway.
22. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med. 186:1997;229-238.
23. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall FK, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med. 186:1997;645-653.
24. + CTLs.
25. + CTLs.
26. + CTLs.
27. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:1994;961-965.
28. + T cells in cancer immunotherapy. Curr Opin Immunol. 6:1994;741-745.
29. + HLA class II-restricted T cell clones against a human sarcoma. J Immunol. 156:1996;2205-2213.
30. + HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma antigens. Int J Cancer. 72:1997;403-407.
31. Wen YJ, Lim SH. T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur J Immunol. 27:1997;1043-1047.
32. + T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antien-presenting cells exposed to b3a2 containing cell lysates. Blood. 90:1997;290-297.
33. De Gruijl TD, Bontkes HJ, Walboomers JMM, Stukart MJ, Doekhie FS, Remmink AJ, Helmerhorst TJM, Verheijen RHM, Duggan-Keen MF, Stern PL, et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistance in patients with cervical neoplasia: a longttudinal study. Cancer Res. 58:1998;1700-1706.
34. + T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res. 55:1995;2984-2987.
35. + hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma. Cell Immunol. 177:1997;176-181.
36. + T lymphocytes and human squamous cell carcinoma of the head and neck. Cell Immunol. 177:1997;35-48.
37. Gjertsen MK, Saeterdal I, Thorsby E, Gaudernack G. Characterization of immune responses in pancreatic carcinoma patients with mutant p21 ras peptide vaccination. Brit J Cancer. 74:1996;1828-1833.
38. + T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer. 72:1997;784-790.
39. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 4:1998;328-332.
40. Ellem KA, O'Rourke MG, Johnson GR, Parry G, Misko IS, Schmidt CW, Parsons PG, Burrows SR, Cross S, Fell A, et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma a cells for immunotherapy. Cancer Immunol Immunother. 44:1997;10-20.
41. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA. 91:1994;9461-9465.
42. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med. 183:1996;1965-1971.
43. Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity. 2:1995;45-59.
44. + T lymphocytes. Proc Amer Assoc Cancer Res. 39:1998;261.
45. Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. 57:1997;3238-3244.
46. Tureci O, Sahin U, Schobert I, Koslowski M, Scmitt H, Schild HJ, Stenner F, Seitz G, Rammensee HG, Pfreundschuh M. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 56:1996;4766-4772.
47. Chen YT, Scanian MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 94:1997;1914-1918.
48. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 187:1998;265-270.
49. Jager E, Jager D, Karbach J, Zidianakis Z, Knuth A. Simultaneous humoral and cellular immune responses against 'cancer - testis' antigen NY-ESO-1: implications for NY-ESO-1-specific immunotherapy. Proc Amer Assoc Cancer Res. 39:1998;368.